Drug Trial Radar · NCT00808067
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial
Last checked: Nov 20, 2026Latest source record: Jun 9, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5,897
Actual
Start
Nov 2008
Primary completion
Dec 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Dec 15, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purposes of this study are: 1. To evaluate the long-term safety of dabigatran etexilate 2. To assess the effect of a knowledge translation intervention on patient outcomes
Conditions
- Atrial Fibrillation
Interventions
dabigatran dose 1Drug
dabigatran high dose twice daily
dabigatran dose 2Drug
dabigatran low dose twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Bleeding, Annualized Rate of Subjects With Major BleedsTime frame: up to 43 months
Locations
567 sites in 35 countries. Site status is shown where the registry gives one.
1160.71.0046 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1160.71.0057 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1160.71.0211 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1160.71.0115 Boehringer Ingelheim Investigational Site
Mobile, Alabama
1160.71.0104 Boehringer Ingelheim Investigational Site
Lake Havasu City, Arizona
1160.71.0185 Boehringer Ingelheim Investigational Site
Tucson, Arizona
1160.71.0038 Boehringer Ingelheim Investigational Site
Hot Springs, Arkansas
1160.71.0302 Boehringer Ingelheim Investigational Site
Jonesboro, Arkansas
1160.71.0191 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
1160.71.0213 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas
1160.71.0441 Boehringer Ingelheim Investigational Site
Carmichael, California
1160.71.0333 Boehringer Ingelheim Investigational Site
Fullerton, California
1160.71.0384 Boehringer Ingelheim Investigational Site
La Jolla, California
1160.71.0246 Boehringer Ingelheim Investigational Site
Lancaster, California
1160.71.0070 Boehringer Ingelheim Investigational Site
Merced, California
1160.71.0349 Boehringer Ingelheim Investigational Site
Oakland, California
1160.71.0016 Boehringer Ingelheim Investigational Site
Oceanside, California
1160.71.0459 Boehringer Ingelheim Investigational Site
Pasadena, California
1160.71.0270 Boehringer Ingelheim Investigational Site
Poway, California
1160.71.0135 Boehringer Ingelheim Investigational Site
Riverside, California
1160.71.0300 Boehringer Ingelheim Investigational Site
Sacramento, California
1160.71.0284 Boehringer Ingelheim Investigational Site
San Diego, California
1160.71.0379 Boehringer Ingelheim Investigational Site
Walnut Creek, California
1160.71.0321 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado
1160.71.0449 Boehringer Ingelheim Investigational Site
Colorado Springs, Colorado
1160.71.0360 Boehringer Ingelheim Investigational Site
Denver, Colorado
1160.71.0413 Boehringer Ingelheim Investigational Site
Denver, Colorado
1160.71.0362 Boehringer Ingelheim Investigational Site
Fort Collins, Colorado
1160.71.0278 Boehringer Ingelheim Investigational Site
Bridgeport, Connecticut
1160.71.0482 Boehringer Ingelheim Investigational Site
Guilford, Connecticut
1160.71.0382 Boehringer Ingelheim Investigational Site
Boynton Beach, Florida
1160.71.0056 Boehringer Ingelheim Investigational Site
Brandon, Florida
1160.71.0296 Boehringer Ingelheim Investigational Site
Clearwater, Florida
1160.71.0327 Boehringer Ingelheim Investigational Site
Coral Springs, Florida
1160.71.0376 Boehringer Ingelheim Investigational Site
Daytona Beach, Florida
1160.71.0074 Boehringer Ingelheim Investigational Site
Fort Myers, Florida
1160.71.0089 Boehringer Ingelheim Investigational Site
Jacksonville, Florida
1160.71.0232 Boehringer Ingelheim Investigational Site
Jacksonville, Florida
1160.71.0427 Boehringer Ingelheim Investigational Site
Jacksonville, Florida
1160.71.0012 Boehringer Ingelheim Investigational Site
Lakeland, Florida
Showing 40 of 567 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.